01 7Adcirca
02 10Cialis
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 107
2018 Revenue in Millions : 324
Growth (%) : -67
Main Therapeutic Indication : Urology
Currency : USD
2020 Revenue in Millions : 607
2019 Revenue in Millions : 891
Growth (%) : -32
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 67
2019 Revenue in Millions : 107
Growth (%) : -37
Main Therapeutic Indication : Urology
Currency : USD
2021 Revenue in Millions : 719
2020 Revenue in Millions : 607
Growth (%) : 18
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 56
2020 Revenue in Millions : 67
Growth (%) : -17
Main Therapeutic Indication : Urology
Currency : USD
2022 Revenue in Millions : 587
2021 Revenue in Millions : 719
Growth (%) : -18
Main Therapeutic Indication : Urology
Currency : USD
2023 Revenue in Millions : 381
2022 Revenue in Millions : 587
Growth (%) : -35
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 41
2021 Revenue in Millions : 56
Growth (%) : -26
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 29
2022 Revenue in Millions : 41
Growth (%) : -30
Main Therapeutic Indication : Sexual Health
Currency : USD
2015 Revenue in Millions : 2,291
2014 Revenue in Millions : 2,311
Growth (%) : 1%
LOOKING FOR A SUPPLIER?